Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

Exclusion Criteria

• Inclusion Criteria
• -Are at least 12 years of age and no older than 65 years
• -Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis
• -Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to medium doses of ICS (alone or in combination with LABA), used regularly as maintenance asthma therapy
• -Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society [ATS]/European Respiratory Society [ERS] acceptability/repeatability criteria
• -Pre-bronchodilator FEV1 of ≥40 to <90% predicted normal value after withholding SABA for ≥6 hours
• -Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1 of ≥15%
• - only 2 reversibility testing attempts are allowed
• -Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)
• -Oral corticosteroid use (any dose) within 6 weeks
• -Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana)
• -Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)
• -Historical or current evidence of a clinically significant disease
• -Cancer not in complete remission for at least 5 years
• -Hospitalized for psychiatric disorder or attempted suicide within 1 year
• -Unable to abstain from protocol-defined prohibited medications during the study